RWM
ORMP icon

Ritholtz Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Ritholtz Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406K Sell
84,347
-71,132
-46% -$283K 0.01% 931
2026
Q1 		$529K Buy
+155,479
New +$527K 0.01% 772

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ritholtz Wealth Management's ORMP Position: Q2 2026 in Review

Ritholtz Wealth Management reduced its Oramed Pharmaceuticals (ORMP) stake by 46% in Q2 2026, selling an estimated $283K and leaving 84,347 shares worth $406K. The position accounts for 0.01% of the portfolio, ranked #931.

Ritholtz Wealth Management first reported a position in ORMP in Q1 2026 and has held it in 2 quarters since. The position peaked at $529K in Q1 2026. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Ritholtz Wealth Management held 84,347 shares of Oramed Pharmaceuticals worth $406K as of Q2 2026.
  • Ritholtz Wealth Management sold 71,132 Oramed Pharmaceuticals shares in Q2 2026, an estimated $283K.
  • Oramed Pharmaceuticals made up 0.01% of Ritholtz Wealth Management's portfolio in Q2 2026, its #931 holding.
  • Ritholtz Wealth Management first reported a position in Oramed Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Ritholtz Wealth Management's Oramed Pharmaceuticals position peaked at $529K in Q1 2026.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Ritholtz Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.